What non‑hormonal treatments are recommended for a menopausal adult woman who cannot or prefers not to use estrogen therapy for hot flashes?

Non-Hormonal Treatment for Hot Flashes

For menopausal women with moderate to severe hot flashes who cannot or prefer not to use estrogen therapy, start with SSRIs/SNRIs (specifically venlafaxine 75-150 mg or paroxetine 7.5-25 mg) or gabapentin 900-2400 mg as first-line pharmacological options 1.

Treatment Algorithm

Step 1: Mild Symptoms - Lifestyle Modifications First

For women with mild or less bothersome hot flashes, implement non-pharmacological measures before considering medications 1:

• Lower ambient temperature and use fans
• Dress in layers for easy adjustment
• Avoid alcohol and spicy foods
• Pursue weight loss if overweight or obese (obesity is a risk factor for vasomotor symptoms)
• Reduce stress through relaxation techniques

Step 2: Moderate to Severe Symptoms - First-Line Pharmacological Options

When lifestyle measures are insufficient, choose from three equally recommended first-line medication classes 1:

SSRIs/SNRIs (Preferred by most patients)

• Venlafaxine 75-150 mg daily: Reduces hot flash frequency by ~70% and composite scores by similar amounts
• Paroxetine 7.5-25 mg daily: The only FDA-approved non-hormonal agent for hot flashes; reduces frequency by ~80%
• Desvenlafaxine 100-150 mg daily: Reduces frequency by ~60%
• Escitalopram 10-20 mg daily or Citalopram 10-20 mg daily: Reduce frequency by ~40-50%

Important caveat: Avoid paroxetine in women taking tamoxifen, as it significantly interferes with tamoxifen metabolism to its active metabolite endoxifen 1.

Gabapentin 900-2400 mg daily

• Particularly effective for nighttime hot flashes when given as a single bedtime dose (300-1200 mg)
• Sedative effects work synergistically with vasomotor symptom reduction at night
• Daytime use may cause intolerable lethargy 1
• Four RCTs confirm moderate efficacy 1

Pregabalin 150-300 mg daily (75-150 mg twice daily)

• Reduces hot flash scores by 65-71% compared to 50% with placebo
• Generally well tolerated 1

Head-to-head comparison: When venlafaxine was compared directly to gabapentin, both reduced hot flash scores by 66%, but two-thirds of patients preferred venlafaxine over gabapentin 1.

Step 3: Second-Line Option - Clonidine

For women who fail or cannot tolerate SSRIs/SNRIs, gabapentin, or pregabalin, use clonidine transdermal patches 1:

• Less effective than first-line agents with more side effects
• Transdermal patches preferred over oral tablets for more stable blood levels
• Side effects include dry mouth, postural hypotension, fatigue, and constipation that often limit use 2

Critical Safety Considerations

SSRI/SNRI Contraindications and Cautions 1:

• Absolute contraindications: Prior neuroleptic syndrome, serotonin syndrome, concurrent MAO inhibitor use, hypersensitivity
• Use with caution in: Bipolar disease, uncontrolled seizures, hepatic/renal insufficiency, uncontrolled hyponatremia, poorly controlled hypertension
• Monitor for: Suicidal thoughts (especially first few months), possible increased bone fracture risk
• Drug interaction: Paroxetine with tamoxifen (as noted above)

Gabapentin/Pregabalin Warnings 1:

• May increase suicidal thoughts and behaviors
• Cause drowsiness, dizziness, impaired balance and coordination
• Pregabalin may additionally impair memory and concentration
• Side effects include fatigue, dizziness, peripheral edema 2

Clonidine Contraindications 1:

• Contraindicated in low blood pressure
• May cause lightheadedness, hypotension, headache, constipation

Understanding the Placebo Effect

A critical pitfall: Hot flash studies consistently show a strong placebo effect averaging 30% (range 4-57%), occurring more often in women with high anxiety and stress 1. This means actual drug efficacy must be interpreted in context—the 40-80% reductions reported include this substantial placebo component.

Comparative Efficacy Context

While non-hormonal agents are effective, standard-dose menopausal hormone therapy remains more effective than all non-hormonal options when head-to-head comparisons are considered 1. However, for women with contraindications to estrogen (estrogen-sensitive cancers, thromboembolic disease) or strong preferences against hormones, these non-hormonal options provide meaningful symptom relief with acceptable safety profiles 3, 4.

Practical Prescribing Approach

1. Start with venlafaxine or paroxetine (unless tamoxifen use, then choose venlafaxine or another SSRI/SNRI) as most patients prefer these over gabapentin
2. Consider gabapentin specifically for nighttime-predominant symptoms given its sedative properties
3. Reserve clonidine for treatment failures due to inferior efficacy and tolerability
4. Titrate doses empirically based on individual response and tolerability
5. Monitor for side effects and suicidal ideation in the first few months of SSRI/SNRI or gabapentinoid therapy